↓ Skip to main content

Dove Medical Press

Pediatric ulcerative colitis: current treatment approaches including role of infliximab

Overview of attention for article published in Biologics: Targets & Therapy, June 2012
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
6 X users

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
55 Mendeley
Title
Pediatric ulcerative colitis: current treatment approaches including role of infliximab
Published in
Biologics: Targets & Therapy, June 2012
DOI 10.2147/btt.s31833
Pubmed ID
Authors

Gia M Bradley, Maria Oliva-Hemker

Abstract

Ulcerative colitis is a chronic inflammatory bowel disease that can lead to derangements in the growth, nutritional status, and psychosocial development of affected children. There are several medical options for the induction and maintenance of disease remission, but the benefits of these medications need to be carefully weighed against the risks, especially in the pediatric population. As the etiology of the disease has become increasingly understood, newer therapeutic alternatives have arisen in the form of biologic therapies, which are monoclonal antibodies targeted to a specific protein or receptor. This review will discuss the classical treatments for children with ulcerative colitis, including 5-aminosalicylates, corticosteroids, thiopurine immunomodulators, and calcineurin inhibitors, with a particular focus on the newer class of anti-tumor necrosis factor-α agents.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Germany 1 2%
Qatar 1 2%
Unknown 52 95%

Demographic breakdown

Readers by professional status Count As %
Other 5 9%
Student > Ph. D. Student 4 7%
Researcher 4 7%
Student > Master 3 5%
Student > Postgraduate 2 4%
Other 6 11%
Unknown 31 56%
Readers by discipline Count As %
Medicine and Dentistry 14 25%
Nursing and Health Professions 3 5%
Agricultural and Biological Sciences 3 5%
Immunology and Microbiology 1 2%
Computer Science 1 2%
Other 2 4%
Unknown 31 56%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 July 2018.
All research outputs
#7,771,565
of 25,374,917 outputs
Outputs from Biologics: Targets & Therapy
#98
of 284 outputs
Outputs of similar age
#53,291
of 179,215 outputs
Outputs of similar age from Biologics: Targets & Therapy
#5
of 9 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 179,215 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.